Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Abstract Background The study evaluated the cost of baroreflex activation therapy plus guideline directed therapy (BAT + GDT) compared to GDT alone for HF patients with reduced ejection fraction and New York Heart Association Class III or II (with a recent history of III). Baroreflex activation ther...

Full description

Bibliographic Details
Main Authors: John Bisognano, John E. Schneider, Shawn Davies, Robert L. Ohsfeldt, Elizabeth Galle, Ivana Stojanovic, Thomas F. Deering, JoAnn Lindenfeld, Michael R. Zile
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cardiovascular Disorders
Subjects:
Costs
Economic
Heart failure
Baroreflex activation therapy
Online Access:https://doi.org/10.1186/s12872-021-01958-y

Similar Items

Similar Items